Malignant melanoma: Death by image and ignorance, diagnosis by surgical excision and laboratory investigation

British Journal of Biomedical Science

Volumn 56, Issue 2, 1999, Pages 134-144

  Magennis, D P ^a   Orchard, G E ^b  

^a TORBAY HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Diagnosis; Immunohistochemistry; Melanoma

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LABORATORY DIAGNOSIS; MELANOMA; PRIORITY JOURNAL; RISK FACTOR; STAINING;

FEMALE; HUMANS; MALE; MELANOMA; RISK FACTORS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032782937     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Austoker J. Melanoma: prevention and early diagnosis. BMJ 1994; 308:1682-6.
2. Simandl G. Alterations in skin function and integrity. In: Porth CM, ed. Pathophysiology, 3rd edn. Philadelphia, PA: JB Lippincott, 1990: 139-41.
3. Gown AM, Vogel AM, Hoak D, McNutt MA. Monoclonal antibodies specific for melanocytic tumours distinguish subpopulations of melanocytes. Am J Pathol 1986; 122:195-203.
4. Glass AG, Hoover RN. The emerging epidemic of melanoma and squamous cell skin cancer. JAMA 1989; 262:2097-100.
5. Rigel DS, Kopf AW, Friedman RJ. The rate of malignant melanoma in the United States: are we making an impact? J Am Acad Dermatol 1987; 17:1050-3.
6. National Cancer Institute. Cancer statistics review 1973-1987 (NIH publication No. 90-2789). Bethesda, MD: Department of Health and Human Services, 1990.
7. Koh HK. Cutaneous melanoma. New Engl J Med 1991; 325:171-82.
8. Swerdlow AJ, English JS, MacKie RM. Fluorescent lights, ultraviolet lamps, and risk of cutaneous melanoma. BMJ 1988; 297:647-9.
9. Walter SD, Marrett LD, From L, Hertzman C, Shannon HS, Roy P. The association of cutaneous malignant melanoma with the use of sunbeds and sunlamps. Am J Epidemiol 1990; 131:232-43.
10. Fitzpatrick TB. The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 1988; 124:869-71.
11. Armstrong BK. Epidemiology of malignant melanoma: interminent or total accumulated exposure to the sun. J Dermatol Surg Oncol 1988; 14:835-49.
12. Lew RA, Sober AJ, Cook N, Marvell R, Fitzpatrick TB. Sun exposure habits in patients with cutaneous melanoma: a case control study. J Dermatol Surg Oncol 1983; 9:981-6.
13. Holman CDJ, Armstrong BJ, Heenan PJ. Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. J Natl Cancer Inst 1986; 76:403-14.
14. Mooi WJ. The dysplastic naevus. J Clin Pathol 1997; 50:711-15.
15. Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985; 102:458-65.
16. Lorentzen M, Pers M, Bretteville-Jensen G. The incidence of malignant transformation in giant pigmented nevi. Scand J Plast Reconstr Surg 1977; 11:163-7.
17. Clark WH Jr, From L, Bernardino A, Mihm MC. The histogenesis and biologic behaviour of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705-27.
18. Krementz ET, Reed JR, Coleman WP III, Sutherland CM, Carter RD, Campbell M. Acral lentiginous melanoma: a clinicopathologic entity. Ann Surg 1982; 195:632-45.
19. Sober AJ, Fitzpatrick TB, Mihm MC et al. Early recognition of cutaneous melanoma. JAMA 1979; 242:2795-9.
20. MacKie RM. Skin cancer: how to spot patients at risk. Monitor Weekly 1993; 21:47-50.
21. Orchard G, Wilson Jones E. Immunocytochemistry in the diagnosis of malignant melanoma. Br J Biomed Sci 1994; 51:44-56.
22. Ordonez NG, Xiaolong J, Hickey RC. Comparison of HMB-45 monoclonal antibody and S-100 protein in the immunohistochemical diagnosis of melanoma. Am J Clin Pathol 1988; 90:385-90.
23. Ciemente C, Cochran AJ, Elder DE et al. Histopathologic diagnosis of dysplastic nevi: concordance among pathologists convened by the World Health Organisation Melanoma Programme. Hum Pathol 1991; 22:313-19.
24. Crutcher WA, Sagabiel RW. Prevalence of dysplastic naevi in a community practice. Lancet 1984; i:729.
25. Cook KR, Spears GFS, Elder DE, Greene MH. Dysplastic nevi in a population-based survey. Cancer 1989; 63:1240-4.
26. McQueen A, Smith N. Muir's textbook of pathology, 13th edn. London: Edward Arnold, 1992: Ch 24, p. 11.
27. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902-8.
28. McGregor J, Yu C, Dublin E, Barnes D, Levison D, MacDonald D. p53 immunoreactivity in human malignant melanoma and dysplastic naevi. Br J Dermatol 1993; 128:606-11.
29. Stevens A, Chalk BT. Pigments and minerals. In: Bancroft JD, Stevens A, eds. Theory and practice of histological techniques, 4th edn. London: Churchill Livingstone, 1996: 243-68.
30. Chen Y-T, Stockert E, Tsang S, Coplan KA, Old LJ. Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 1995; 92:8125-9.
31. Walts AE, Said JW, Shintaku P. Cytodiagnosis of malignant melanoma: immunoperoxidase staining with HMB-45 antibody as an aid to diagnosis. Am J Clin Pathol 1988; 90:77-80.
32. Henderson DW, Papadimitriou JM. Ultrastructural appearance of tumors. London: Churchill Livingstone, 1982:100-6.
33. Erlandson RA. Ultrastructural diagnosis of amelanotic malignant melanoma: aberrant melanosomes, myelin figures or lysosomes. Ultrastruct Pathol 1987; 11:191-208.
34. Anstey A, Cerio R, Ramnarain D et al. Desmoplastic malignant melanoma: an immunocytochemical study of 25 cases. Am J Dermatopathol 1994; 16:14-22.
35. Nakajima T, Watanabe S, Sato Y, Kameta T, Shimosato Y, Ishihara K. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 1982; 50:912-18.
36. Kahn HJ, Marks A, Thom H, Baumal R. Role of antibody to S100 protein in diagnostic pathology. Am J Clin Pathol 1983; 79:341-7.
37. Vennegoor C, Culafat J, Hageman P et al. Biochemical characterisation and cellular localisation of a formalin-resistant melanoma-associated antigen reacting with monoclonal antibody NKI/C3. Int J Cancer 1985; 35:287-95.
38. MacKie R, Campbell I, Turbin M. Use of NKI/C3 monoclonal antibody in the assessment of benign and malignant lesions. J Clin Pathol 1984; 37:367-72.
39. Buley I, Gatter K, Kelly P et al. Granular cell tumours revisited. An immunohistological and ultrastructural study. Histopathology 1988; 12:263-74.
40. Calonje E, Wilson Jones E, Smith N et al. Cellular neurothekeoma: an epithelioid variant of pilar leiomyoma? Morphological and immunohistochemical analysis of a series. Histopathology 1992; 20:397-404.
41. DAKO data sheet. Monoclonal antibody to HMB-45. 1998.
42. Skelton III H, Smith K, Barrett T et al. HMB 45 staining in benign and malignant melanocytic lesions. Am J Dermatopathol 1991; 13:543-50.
43. Palazzo J, Duray P. Congenital aminated Spitz nevi immunoreactivity with a melanoma-associated monoclonal antibody. J Cutan Pathol 1988; 15:166-70.
44. Palazzo J, Duray P. Typical dysplastic, congenital and Spitz nevi - a comparative immunohistochemical study. Hum Pathol 1989; 20:341-6.
45. Esclamado RM, Gown AM, Vogel AM. Unique proteins defined by monoclonal antibodies specific for human melanoma - some potential clinical applications. Am J Surg 1986; 152:376-84.
46. Nakajima T, Watanabe S, Sato Y, Kameta T, Hirota T, Shimosato Y. An immunoperoxidase study of S100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol 1982; 6:715-27.
47. Bonetti F, Pea M, Martignoni G et al. False-positive immunostaining of normal epithelia and carcinomas with ascites fluid preparations of antimelanoma monoclonal antibody HMB45. Am J Clin Pathol 1991; 95:454-9.
48. Wick M, Swanson P, Rocamara A. Recognition of malignant melanoma by monoclonal antibody HMB 45. An immunohistochemical study of 200 paraffin-embedded cutaneous tumors. J Cutan Pathol 1988; 15:201-7.
49. Skelton H, Smith K, Maceira J et al. HMB 45 negative spindle cell melanoma. J Cutan Pathol 1992; 19:550 (Abstr).
50. Orchard G. Cutaneous malignant melanoma: Part II. Cell Pathol Abstr 1992; 14:3.
51. Orchard G. Melan A (MART-1): a new monoclonal antibody for malignant melanoma diagnosis. Br J Biomed Sci 1998; 55:8-9.
52. Chen Y-T, Stockert E, Jungbluth A et al. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci USA 1996; 93:5915-19.
53. Blessing K, Sanders DS, Grant JJ. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 1998; 32(2): 139-46.
54. Coulie PG, Brichard V, Van Pel A, Wolfer T, Schneider J, Traversari C, Mattei S, De Plaen E, Lurquin C, Szikora JP, Renauld JC, Boon T. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1994; 180:35-42.
55. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognised by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994; 91:3515-19.
56. Kaufman O, Koch S, Burghart J, Audring H, Dietel M. Tyrosinase, melan-A and KBA62 as markers for the immunohistochemical identification of metastatic amelanotic melanomas on paraffin sections. Mod Pathol 1998; 11(8):740-6.
57. Rudolph P, Schubert C, Schubert B, Parwaresch R. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J Am Acad Derm 1997; 37:169-78.
58. Veronesi U, Cascinelli N, Adamus J et al. Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318:1159-62.
59. Hill GJ II, Krementz ET, Hill HZ. Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. Cancer 1984; 53:1299-305.
60. Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys 1986; 12:867-72.